A systems pharmacology approach to biobetter can provide a distinct competitive advantage. For biobetter a lot of information on the target and disease are available. Together with the pharmacokinetic knowledge a systems pharmacology model can be used to optimally design a biobetter and define the right selection criteria to select the most competitive compound. During the entire development process the systems pharmacology model can be updated with new experimental information, translated to human and benchmarked against the original competitor compound. This ensure robust and fast decision making with the confidence in developing a compound with a superior pharmacological profile.